Regenxbio (RGNX) Misses Q3 EPS by 29c; Reports $533.5M of Cash and Cash Equivalents

Regenxbio (NASDAQ: RGNX) reported Q3 EPS of ($1.37), $0.29 worse than the analyst estimate of ($1.08). Revenue for the quarter came in at $30.8 million versus the consensus estimate of $41.46 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Six Flags names Mark Pauls as chief operating officer
• SWBI beats estimates by 71%, GEO nears 52-week high on policy tailwinds